An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy PSA level [ Time Frame: Every 3 months during 27 months of treatment ] [ Designated as safety issue: Yes ]

• Country None
• organs None
• Specialty None

An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy To evaluate safety and tolerability during long-term treatment with degarelix one-month dosing regimen in prostate cancer patients

• Country None
• organs None
• Specialty None

A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation and pregnancy rates in IVF/ICSI patients – To evaluate the effect of barusiban compared to placebo on implantation rate in IVF/ICSI patients

• Country None
• organs None
• Specialty None

PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo To demonstrate that a daily dose of 6 g PENTASA Sachet administered as a 2 g morning dose and a 4 g evening dose during a period of 10 weeks is superior to placebo in active mild to moderate CD in ter...

• Country None
• organs None
• Specialty None

EQUIPO (Efecto de Quinagolida en la Prevención de OHSS) Estudio de prueba de hipótesis, aleatorizado, doble ciego, de grupos paralelos, en búsqueda de dosis, controlado con placebo, multicéntrico, para la determinación del efecto de 3 semanas de tratamiento, con una de las tres dosis orales de Quinagolida (50, 100, 200 μg/día) y placebo, para la prevención del síndrome de hiperestimulación ovárica en mujeres con hiperestimulación ovárica controlada en técnicas de reproducción asistida To identify the effective doses of quinagolide, including the lowest effective dose, compared to placebo in preventing moderate/severe early ovarian hyperstimulation syndrome (OHSS)

• Country None
• organs None
• Specialty None

An Open-label, Multi-centre, Phase III Study of Local Tolerability of Zomacton 10 mg (Recombinant Somatropin) administered by ZomaJet Vision X To assess the local tolerability of an individualised dose of Zomacton 10 mg administered by ZomaJet Vision X

• Country None
• organs None
• Specialty None

A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of volume reduction of the prostate in patients with prostate cancer being candidates for medical castration Demonstrate that treatment with degarelix in terms of mean percentage reduction in prostate volume measured with trans-rectal ultrasound (TRUS) is non-inferior to treatment with goserelin plus bicalut...

• Country None
• organs None
• Specialty None

A randomised, open-label, parallel-group, multi-centre trial comparing the efficacy and safety of 12 months treatment with one daily dose of ZOMACTON® to one daily dose of GENOTROPIN® in the treatment of children with idiopathic growth hormone deficiency To demonstrate that one daily dose of ZOMACTON (10 mg/mL) is equivalent to one daily dose of GENOTROPIN (12 mg/mL) in terms of growth measured as height velocity based on 12 months of treatment.

• Country None
• organs None
• Specialty None

A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients with Prostate Cancer The primary objective is to compare the severity of ISR related pain following degarelix s.c. administrations with two different injection techniques and i.m. administration in prostate cancer patient...

• Country None
• organs None
• Specialty None

A Phase 3b, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients with Prostate Cancer To investigate the long-term safety of the dose regimen of degarelix proposed for marketing in patients with prostate cancer.

• Country None
• organs None
• Specialty None